Gevorg Tamamyan: I urge Agenus to consider Armenia as the first country to register BOT/BAL combination

Gevorg Tamamyan shared on LinkedIn:

“As I mentioned in my earlier post, we are ready in Armenia! I urge my dear friends at Agenus to consider Armenia as the first country to register BOT/BAL combination! We started the clinical trial for another indication – Non-Small Cell Lung Cancer (NCT06322108) just a month ago and in one month already 3 patients enrolled and 1 is in the process of enrollment! The team is ready and we will be happy to host and provide care for any patient from around the world! ”

Source: Gevorg Tamamyan/LinkedIn

Gevorg Tamamyan is the Editor-in-chief of OncoDaily, President-Elect of SIOP Asia Continental Branch and Pediatric Oncology East and Mediterranean (POEM) Group, and the CEO of the Immune Oncology Research Institute (IMMONC).

He is a Co-Founder and Board Member of the Armenian Association of Hematology and Oncology, City of Smile Charitable Foundation, Co-Founder and Chairman of the Board of the Institute of Cancer and Crisis, the Former President of the Harvard Club of Armenia.